Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events-Reference-Cited by-同舟云学术

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Published:2018-11-19 Issue:11 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Zhan Shipeng¹,Tang Min¹,Liu Fang¹,Xia Peiyuan¹,Shu Maoqin²,Wu Xiaojiao³

Affiliation:

1. First Affiliated Hospital of Third Military Medical University (Army Medical University); Pharmacy Department; 30 Gaotanyan Street Shapingba District Chongqing China 400038

2. First Affiliated Hospital of Third Military Medical University (Army Medical University); Cardiovascular Department; Chongqing China

3. Third Military Medical University (Army Medical University); Department of Health Statistics, College of Preventive Medicine; Chongqing China

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/epdf/full

Reference246 articles.

1. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia;Ballantyne;International Journal of Clinical Practice,2004

2. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study;Oikawa;Journal of Atherosclerosis & Thrombosis,2017

3. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study;Oikawa;Atherosclerosis,2016

4. UMIN000001224 Effect of fenofibrate and ezetimibe combination treatment on lipid http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000001224

5. The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression;Kastelein;Atherosclerosis Supplements,2003

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis;Annals of Medicine;2024-08-10

2. Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis;Clinical Cardiology;2024-08

3. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study;Lipids in Health and Disease;2024-06-03

4. Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event;Atherosclerosis;2024-06

5. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings;Advances in Therapy;2024-04-30